2,107,175 Shares in Armata Pharmaceuticals, Inc. $ARMP Bought by Madison Asset Management LLC

Madison Asset Management LLC bought a new stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,107,175 shares of the company’s stock, valued at approximately $13,654,000. Madison Asset Management LLC owned 0.06% of Armata Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Deutsche Bank AG acquired a new stake in Armata Pharmaceuticals during the 2nd quarter worth about $78,000. Jane Street Group LLC acquired a new position in shares of Armata Pharmaceuticals in the 4th quarter valued at about $108,000. Bank of America Corp DE lifted its holdings in shares of Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after buying an additional 8,198 shares during the period. Millennium Management LLC purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth about $164,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth about $177,000. 3.57% of the stock is owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Price Performance

ARMP opened at $5.07 on Thursday. The firm has a fifty day moving average price of $5.41 and a 200 day moving average price of $8.08. Armata Pharmaceuticals, Inc. has a 1 year low of $2.40 and a 1 year high of $16.34. The stock has a market cap of $188.50 million, a P/E ratio of -0.67 and a beta of 1.30.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The company had revenue of $2.51 million for the quarter, compared to analyst estimates of $0.40 million. Equities analysts expect that Armata Pharmaceuticals, Inc. will post 0.5 EPS for the current year.

Analyst Ratings Changes

Separately, Zacks Research raised Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Armata Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.